BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9660037)

  • 1. Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta.
    Brockmeyer NH; Barthel B; Mertins L; Goos M
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):309-11. PubMed ID: 9660037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections.
    Brockmeyer NH; Mertins L; Spatz D; Tillmann I; Goos M
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):530-3. PubMed ID: 1283384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system.
    Brockmeyer NH; Barthel B; Mertins L; Goos M
    Chemotherapy; 1998; 44(3):174-80. PubMed ID: 9612607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
    Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
    Brockmeyer NH; Tillmann I; Mertins L; Barthel B; Goos M
    Eur J Med Res; 1997 Sep; 2(9):377-83. PubMed ID: 9300934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
    Coverdale SA; Samarasinghe DA; Lin R; Kench J; Byth K; Khan MH; Crewe E; Liddle C; George J; Farrell GC
    Am J Gastroenterol; 2003 Jun; 98(6):1384-90. PubMed ID: 12818285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrine pharmacokinetics and urinary excretion in female horses.
    Dyke TM; Sams RA; Hinchcliff KW
    Am J Vet Res; 1998 Mar; 59(3):280-5. PubMed ID: 9522945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferons in the management of viral hepatitis.
    Zein NN
    Cytokines Cell Mol Ther; 1998 Dec; 4(4):229-41. PubMed ID: 10068057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma.
    Liu G; Zhai Q; Schaffner DJ; Wu A; Yohannes A; Robinson TM; Maland M; Wells J; Voss TG; Bailey C; Alibek K
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):201-6. PubMed ID: 15039095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.
    Kansu A; Kuloğlu Z; Demirçeken F; Girgin N
    Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.